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Abstract 
We verified a physiologically-based pharmacokinetic (PBPK) model to predict cytochrome 
P450 3A4/5-mediated drug-drug interactions (DDIs).  A midazolam-ketoconazole interaction 
study in 24 subjects selected by CYP3A5 genotype, and LC/MS-quantification of CYP3A4/5 
abundance from independently acquired and genotyped human liver (n=136) and small 
intestinal (N=12) samples were conducted.  The observed CYP3A5 genetic effect on 
midazolam systemic and oral clearance was successfully replicated by a mechanistic 
framework incorporating the proteomics-informed CYP3A abundance and optimized small 
intestinal CYP3A4 abundance based on midazolam intestinal availability (FG) of 0.44.  
Furthermore, combined with a modified ketoconazole PBPK model, this framework 
recapitulated the observed geometric mean ratio of midazolam area under the curve 
(AUCR) following 200mg or 400mg ketoconazole, which was, respectively, 2.7-3.4 and 3.9-
4.7 fold in intravenous administration, and 11.4-13.4 and 17.0-19.7 fold in oral 
administration, with AUCR numerically lower (P>0.05) in CYP3A5 expressers than non-
expressers.  In conclusion, the developed mechanistic framework supports dynamic 
prediction of CYP3A-mediated DDIs in study planning by bridging DDIs between CYP3A5 
expressers and non-expressers.   
 
Introduction  
Cytochrome P450 3A4/5-mediated interactions continue to be commonly encountered as 
these enzymes are involved in the metabolic clearance and systemic bioavailability of more 
than half of the marketed drugs [1].  In adults, CYP3A4 and CYP3A5 are the most abundant 












This article is protected by copyright. All rights reserved. 
substrates displays considerable inter-individual variability due to environmental, dietary, 
pathologic and genetic modulation of enzyme activity at both hepatic and intestinal sites 
[3]: CYP3A4 genetic variation only explains approximately 5% of variability [4].  In contrast, 
genetic polymorphisms of CYP3A5 significantly contribute to the inter-individual variability 
in metabolic clearance of some CYP3A-metabolized drugs [5].  CYP3A5*3 is the most 
common non-functional CYP3A5 allele [6] with differential distribution among ethnic groups 
[7].  CYP3A4 and CYP3A5 also share many common substrates, and the inhibition potency of 
many CYP3A inhibitors differ for CYP3A4 and CYP3A5 [8], further adding to the complexity of 
CYP3A-mediated DDIs.    
Prediction of the magnitude of CYP3A-mediated DDIs is challenging.  Physiologically-based 
pharmacokinetic (PBPK) modeling has not been successful in bringing together the relevant 
drug properties, physiological components including liver and gut CYP3A4/5, and the 
CYP3A5 genetic polymorphism to predict CYP3A-mediated DDIs.  One of the contributing 
factors is lack of characterization of gut CYP3A interactions and outcomes following 
perturbation of the system by inhibition.  Furthermore, limited well-characterized data exists 
that adequately describes the expressions and relationships of gut CYP3A4 and CYP3A5.   
 
We therefore had two objectives in the study.  Our first objective is to deconvolute the 
complex interactions between liver and gut CYP3A4 and CYP3A5 using a clinical CYP3A-
mediated DDI study with intravenous and oral administration of a CYP3A substrate in 
different CYP3A5 genotypes.  We hypothesized that for a CYP3A inhibitor that preferentially 
inhibits CYP3A4, magnitude of CYP3A inhibition may differ between CYP3A5 expressers, i.e. 












This article is protected by copyright. All rights reserved. 
individuals who do not have functional CYP3A5.  Ketoconazole was chosen as the clinical 
CYP3A inhibitor because it preferentially inhibits CYP3A4 [9] and has been commonly used 
to define CYP3A involvement in the systemic availability and/or clearance of a CYP3A 
substrate.  Midazolam was selected as the CYP3A substrate as both CYP3A4 and CYP3A5 
efficiently metabolize it in vitro [10]. Furthermore, its systemic clearance and oral 
bioavailability are commonly used to quantify clinical CYP3A activity because it displays 
substantial and selective metabolism by gut and liver CYP3A enzymes with minimal influence 
of drug transporters [11].  Our second aim is to exploit a PBPK modeling approach to predict 
CYP3A-mediated DDIs by integrating LC/MS measured CYP3A abundance and optimized 
small intestinal CYP3A4 abundance.  We employ a single compartment first-order absorption 
model but recognize that a more complex segmented model of the gastro-intestinal tract 
will be necessary to recover drug-drug interactions for a drug that undergoes distal 
absorption [12].   Modeling not only helps understand and rationalize the clinical study 
results, but also allows prediction of situations where CYP3A5 genotypes may cause 
differences in CYP3A-mediated drug disposition and DDIs.    
 
RESULTS 
Clinical Midazolam- Ketoconazole Interaction Study  
The serum concentration-time profiles of midazolam by CYP3A5 genotypes following 
intravenous and oral doses are shown in Figure 1.  Initial CYP3A5*3 genotyping resulted in 
eight subjects in each of the CYP3A5*1/*1, CYP3A5*1/*3 and CYP3A5*3/*3 groups.  
Subsequent genotyping for CYP3A5*6 and CYP3A5*7 revealed CYP3A5*1/*6 and 
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CYP3A5*3/*7 being considered individually as its phenotype cannot be unequivocally 
assigned [13]. The groups with ≥1 copy of the CYP3A5*1 were combined into one CYP3A5 
expresser group as they did not differ statistically significantly in Cmax and clearance values.  
Compared to CYP3A5 non-expressers, oral clearances of midazolam (CLpo) were not 
significantly higher (geometric mean±SD) (140±66 vs 105±41 L/hr, P=0.13), but systemic 
clearances of midazolam (CLsys) were significantly higher (32.8±7.95 vs 24.1±4.19 L/hr, 
P=0.002), and Cmax values were significantly lower (1.6±0.6 vs 2.4±0.6, P=0.011) in CYP3A5 
expressers.  Hepatic extraction ratio in CYP3A5 expressers was approximately 30% higher 
than that of non-expressers (0.30±0.10 vs 0.22±0.04), but intestinal availability (FG) in both 
groups was comparable (0.35±0.09 vs 0.33±0.06), suggesting lack of correlation between 
intestinal and hepatic availability of orally administered midazolam and differential 
regulation of hepatic and intestine CYP3A4, similar to other studies [11, 14].     
 
As expected, ketoconazole 200 and 400 mg doses had a similar effect on midazolam Cmax as 
both doses caused almost complete inhibition of gut CYP3A. The increase in midazolam AUC 
at the 400 mg ketoconazole dose was greater than that observed at the 200 mg dose but 
not proportional to the increase in ketoconazole exposure as the maximal inhibition of 
CYP3A in the liver is approached (Table 1).  CLsys values (geometric mean±SD) in CYP3A5 
expressers and non-expressers were, respectively, 12.1±4.62 and 7.1± 2.0 L/hr after 200 mg, 
and 8.4±2.8 and 5.2±1.4 L/hr after 400 mg ketoconazole.  CLpo values in CYP3A5 expressers 
and non-expressers were, respectively, 13.3± 5.6 and 7.0±2.0 L/hr after doses of 200 mg, 
and 8.4±3.5 and 4.9±1.3 L/hr after 400 mg ketoconazole.  In other words, following 200mg 
or 400mg ketoconazole, the geometric mean ratio of the midazolam AUC (AUCR) was, 
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17.0-19.7 fold in oral administration, but was not associated with CYP3A5 genotype (Table 
S1).  Additionally, there was no significant difference in the AUC 0-10hr of ketoconazole 200 
mg or 400 mg between the 6th and 7th day of dosing (Figure S1), nor significant differences in 
ketoconazole PK parameters among the groups with different copies of CYP3A5*1 allele for 
any given ketoconazole dose (Table S2). Inclusion of the CYP3A5*3/*7 individual in the 
group with 0 or 1 copy of CYP3A5*1 did not influence any of these findings above (data not 
shown).   
 
CYP3A Abundance and Midazolam Hydroxylation Activity   
Proteomic analyses [15, 16] identified large variability in the CYP3A abundance within a 
group of genotyped human liver (N=136) and small intestinal (N=12) samples enriched for 
CYP3A5 expressers (Table 2). As CYP3A5*1/*1 and CYP3A5*1/*3 carriers did not differ in 
midazolam clearance (Table 1), both groups were also combined to increase sample size in 
analyzing CYP abundance.  In CYP3A5 expressers, hepatic and small intestinal CYP3A5, but 
not CYP3A4 abundance (P>0.05), was significantly higher than those of non-expressers 
(Table 2). Within CYP3A5 expressers, significant correlation between CYP3A4 and CYP3A5 
abundance was observed in liver (Fig. 2a, Rs 0.63, P<0.05) and small intestine (Fig. 2b, Rs 
0.60, P<0.05).  Additionally, for hepatic (Figure 2c) and small intestinal (Figure 2d) 
microsomal samples, there existed good correlation between total CYP3A abundance and 
activity that was determined by the formation of 1’-hydroxymidazolam at approximately the 
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The mean abundance ratio of small intestinal CYP3A4 and CYP3A5 was determined to be, 
respectively, 6.8 (12.3 to 1.81 pmol/mg) and 175.8 (12.3 to 0.07 pmol/mg) in CYP3A5 
expressers and non-expressers (Table 2).  The CYP3A4 abundance in a PBPK modelling 
software, SimCYP, was increased from 66.2 to 130 nmol/small intestine to reduce MDZ FG 
from 0.56 to 0.44 [11] for CYP3A5 non-expressers.  Subsequently the mean abundance 
ratios were used to adjust the CYP3A5 content in SimCYP from 24.6 and 0, respectively, to 
19.1 and 1.13 nmol/small intestine for CYP3A5 expressers and non-expressers, respectively.  
 
Simulation of CYP3A5 Genetic Impact on Midazolam in vivo Clearance.  The capability of 
PBPK models to reproduce midazolam blood clearance vs time profiles incorporating 
different hepatic and small intestinal CYP3A abundance in both CYP3A5 phenotypes were 
compared (Table 3 and Table S3).  The proteomics-informed CYP3A abundance and 
variability that included 33% of measured coefficient of variance (CV) value from the human 
liver microsomal samples in conjunction with optimized small intestinal CYP3A abundance 
(scenario 5, Table S3) performed best and was utilized for subsequent simulations unless 
noted.   
    
Simulation of CYP3A5 Genetic Effects on Tacrolimus in vivo Clearance. CYP3A5 genetic 
effects have been consistently demonstrated on tacrolimus clearance [5]. Using the 
proteomics-informed CYP3A abundance and variability, the modified tacrolimus SimCYP 
compound file (Table S4) adequately recovered the observed oral blood clearance in 
CYP3A5 expressers and non-expressers (Table S5a), and the PK in Caucasians and Africans 
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Simulation of Midazolam-Ketoconazole Interactions. The modified ketoconazole model in 
SimCYP (Table S6) adequately recovered the serum PK of ketoconazole orally administered 
at 200mg and 400 mg (Figure S3a and S3b), but under-estimated those following 600 mg 
and 800 mg dose (data not shown).  Among the 17 published midazolam- ketoconazole 
interaction studies with different study designs [17], 65% (11/17) of the study point 
estimates of AUCR, and 82% (14/17) of the 90% confidence interval were estimated within 
1.5-fold of the observed (Figure S4).   
 
Moreover, by integrating the proteomics-informed CYP3A abundance and variability, the 
modified ketoconazole model adequately recovered the inhibition of ketoconazole 200 mg 
and 400 mg QD towards midazolam PK and clearance in CYP3A5 expressers and non-
expressers (Fig. 3a-f and Table S7).  More importantly, the predicted AUCR of midazolam 
following ketoconazole is similar to the observed value, and slightly lower in the CYP3A5 
expressers than non-expressers as observed.  
 
Simulation of the Effects of CYP3A5 Metabolism and Differential Inhibition toward CYP3A5 
and CYP3A4 on CYP3A-Mediated Drug Disposition and DDIs in CYP3A5 Expressers and 
Non-expressers. We formulated hypothetical studies focusing on how co-substrates of 
CYP3A4 and CYP3A5 would change in metabolic clearance and DDIs with two important 
variables: 1) relative contributions of CYP3A5 and CYP3A4 to substrate metabolism, and 2) 
differential inhibitory potential of a CYP3A inhibitor towards CYP3A5 and CYP3A4 (Ki ratio 
(CYP3A5/CYP3A4) or Ki,3A5/Ki,3A4) [18].  CYP3A5 genetic effects on the hypothetical CYP3A 
substrate, as shown by the clearance ratio of expressers to non-expressers, increased with 
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CYP3A5 expressers ranged from 1.2- and 1.4- fold to 2.3- and 4-fold of non-expressers, 
respectively, when the relative contribution of CYP3A5 to metabolism ranges from equal to 
9 times that of CYP3A4.  
 
Following treatment with the hypothetical CYP3A inhibitor, the CLsys and CLpo of a CYP3A 
substrate remained higher in CYP3A5 expressers than non-expressers (data not shown).  
Within a given administration route of the substrate, the magnitude of inhibition within the 
CYP3A5 expressers increased with increasing inhibitory potency toward CYP3A5 (Fig. 4c-4d 
and Table S8). Interestingly, the relative differences of AUCR between CYP3A5 expressers 
and non-expressers varied with the relative CYP3A5 metabolic contribution and the ratio of 
Ki toward CYP3A5 and CYP3A4.  The higher the relative CYP3A5 contribution, the higher the 
Ki,3A5/Ki,3A4  that would need to achieve a comparable or higher AUCR in CYP3A5 expressers 
compared to non-expressers.    
 
DISCUSSION 
In the present study, we have described a clinical CYP3A-mediated DDI study to inform a 
PBPK framework that successfully recapitulated midazolam and ketoconazole interactions in 
the absence and presence of CYP3A5 expression.  The framework builds upon optimized 
small intestinal CYP3A4 abundance and integrates the proteomics-informed CYP3A 
abundance from genotyped human liver (n=136) and small intestinal (N=12) samples.  The 
PBPK model was also qualified by recovering the significant CYP3A5 genetic effects on 
tacrolimus disposition. Hypothetical DDI studies were subsequently simulated to 
demonstrate utility of the framework in predicting CYP3A5 contribution to CYP3A-mediated 












This article is protected by copyright. All rights reserved. 
 
The clinical DDI study was consistent with literature on the overall understanding of 
ketoconazole inhibition and CYP3A5 genetic effects.  First, ketoconazole increased 
midazolam exposure in a dose-dependent manner and also at a magnitude within the 
ranges of the 17 published ketoconazole-midazolam studies [17].  Second, consistent with 
previous findings [5, 19-22], an overall weak influence of CYP3A5 genetics on midazolam 
metabolism was observed.  In this study, CYP3A5 expressers had approximately 30% higher 
CLsys and CLpo relative to non-expressers. But due to the markedly lower inter-individual 
variability for the CLsys (2.3-fold), comparing to that of CLpo (7.0-fold) and other studies (3.3- 
to 5.2-fold) [21-24], only the CLsys change reached statistical (p<0.05, Table 1) with unlikely 
clinical significance.  Third, CYP3A5 genotype appeared to have no significant effect on the 
midazolam AUCR upon ketoconazole treatment, with AUCR only slightly lower (P>0.05) in 
CYP3A5 expressers than non-expressers (Table 1). Although somewhat surprising, this is in 
agreement with the data of Halama et al. that evaluated the interactions of ketoconazole 
400 mg QD with orally administered midazolam [25]. Another potent CYP3A5 competitive 
inhibitor fluconazole also did not result in differential changes of midazolam metabolites 
formation across CYP3A5 genotypes [26].   
 
Importantly, the clinical DDI study allowed a deconvolution of the contribution of CYP3A4 
and CYP3A5 towards first-pass hepatic and gut metabolism, which was critical in qualifying 
our FG optimization approach.  Systemic clearance and AUCR from the midazolam 
intravenous administration in the CYP3A5 non-expressers before and after ketoconazole 
treatments informed estimation of first-pass hepatic CYP3A4 contribution (Table 1).  
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CYP3A4 contribution was delineated (Table 1). In SimCYP, midazolam FG (0.57) was derived 
using plasma clearance and hepatic plasma flow, assuming midazolam partition into red 
blood cells was negligible [27].  This is not necessarily a valid assumption given the 
midazolam blood to serum concentration ratio was 0.56-0.66 at the serum concentration of 
10-150 ng/ml [11].  We aimed to adjust midazolam FG to approximately 0.44 that was 
obtained using blood clearance and hepatic blood flow [11].  Midazolam FG in SimCYP is 
calculated using a Qgut model basing on a nonlinear relationship of gut intrinsic clearance 
and gut blood flow.  As we cannot directly input our small intestinal microsomal CYP3A4 
abundance data into SimCYP due to lack of the data collection parameters needed for 
conversion [28], we optimized it in SimCYP from 66.2 to 130 nmol/small intestine leading to 
midazolam FG of 0.44 in CYP3A5 non-expressers.  This approach drastically improved 
magnitude of CYP3A4-mediated DDI by adequately recovering the first-pass gut CYP3A4 
contribution (Fig. 3 and Table S7).  By contrast, without such optimization, midazolam AUCR 
was markedly under-estimated regardless of ketoconazole model and hepatic CYP3A 
abundance (Table S9).  It should be noted that this optimization of abundance was in the 
context of the single absorption compartment with a first-order model and should be 
revisited if other absorption models are employed. 
  
The proteomics-informed CYP3A abundance has improved the mechanistic framework of 
CYP3A-mediated DDI prediction.  The LC/MS-measured hepatic CYP3A4 content reasonably 
recovered midazolam CLsys in CYP3A5 non-expressers (Table 3&4).  Furthermore, the dataset 
was consistent with the literature: 1) good correlation between the CYP3A abundance and 
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hepatic and small intestinal CYP3A4 abundance did not significantly differ between CYP3A5 
expressers and non-expressers (Table 2); 3) the mean hepatic CYP3A4 and CYP3A5 
abundance (Table 2) was consistent with that from a meta-analysis of 50 studies [30].  
Additionally, as artificial variability exists in human liver banks due to sources, procurement, 
processing, and treatment, hepatic CYP3A4 and CYP3A5 variabilities were reduced from 98% 
and 92% to 32% and 30%, respectively, to improve prediction of variability for CYP3A4 
substrates, similar to previous approaches [31].  The optimized CYP3A4 abundance 
variability of 32% is similar to 33% that was used to simulate the reported CV values of AUC 
for multiple CYP3A4 substrates [32].  
  
The proteomic dataset has re-defined relationships of CYP3A4 and CYP3A5 in liver and gut, 
which were further qualified in the study.  Comparing to the SimCYP values [33], our dataset 
trended lower in hepatic CYP3A4 and CYP3A5 abundance (80.1 and 23.8 versus 137 and 103 
pmol/mg, respectively), and in the CYP3A4 vs CYP3A5 correlation (correlation coefficient 
0.18 versus 0.38) (Table S2).  Additionally, for the first time, the ratios of small intestinal 
CYP3A4 to CYP3A5 abundance in different CYP3A5 phenotypes were characterized (Table 2), 
enabling estimation of the small intestinal CYP3A5 abundance based on the optimized 
CYP3A4 content in SimCYP (Table S2).  The re-defined relationships of CYP3A4 and CYP3A5 in 
liver and gut well recovered CYP3A5 genetic effects on IV and oral clearance of midazolam 
and tacrolimus (Table 3, Table S5 & Figure S2).  Furthermore, they enabled recapitulating the 
slightly lowered midazolam AUCR in the CYP3A5 expressers than non-expressers following 
ketoconazole treatment (Fig. 3).  The Ki values of ketoconazole towards CYP3A4 and CYP3A5 
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CYP3A probe [9].  Under the simulated ketoconazole concentrations in liver and small 
intestine, CYP3A4 activity was inhibited to a larger extent than CYP3A5 as demonstrated by 
the higher hepatic and small intestinal intrinsic clearance in CYP3A5 expressers than non-
expressers (Figure S5a-S5b).  As a result of interplays among uninhibited CYP3A5 protein, 
CYP3A5 metabolic activity, and reduction of CYP3A4 activity ascribed to CYP3A4 inhibition, 
midazolam AUCR in CYP3A5 expressers turned out to be only slightly lower than non-
expressers following ketoconazole treatment.  The utility of the proteomics-informed CYP3A 
abundance and variability in simulating and modeling other CYP3A substrate(s) in SimCYP 
settings warrants further follow up.  
 
Previously, a ketoconazole PBPK model that incorporated a saturable efflux process in the 
liver compartment has improved the prediction of CYP3A inhibition [17, 34]. We have 
translated the approach into SimCYP by engineering uptake and efflux transporter-like 
mechanisms in the liver (Table S6).  The modified model was demonstrated to describe the 
nonlinear ketoconazole accumulation at the enzyme site in a dose-dependent manner 
(Figure S5c-S5d), leading to higher extent of hepatic and intestinal CYP3A inhibition in the 
400mg relative to the 200mg ketoconazole treatment.  The modified model recapitulated 
the inhibition of 200mg and 400 mg ketoconazole QD towards midazolam PK and clearance 
in CYP3A5 expressers and non-expressers (Fig. 3).  By contrast, the SimCYP ketoconazole 400 
mg QD model (v.17R1) would markedly under-estimate such interactions (Table S9).  The 
modified ketoconazole model is a practical solution to predict the worst-case scenario of 
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The mechanistic framework qualified here also illustrated the importance of determining if 
an investigational drug is a substrate and/or inhibitor of CYP3A5 in addition to CYP3A4 and 
has enabled us to predict the impact of CYP3A5 expression on the pharmacokinetics and 
DDIs of CYP3A substrates.  First, fractional clearance of drugs by CYP3A5 (fm, CYP3A5) must be 
at least 0.34 (total hepatic CLint 1234 L/h) for CYP3A5 genetics to become a major 
contributor to total intrinsic clearance (Fig. 4a-4b).  In addition, both the fm, CYP3A5 and the Ki 
ratio (CYP3A5/CYP3A4) (Ki,3A5/Ki,3A4) should be considered when predicting impact of CYP3A5 
expression on a strong CYP3A inhibitor mediated DDIs: 1) If fm, CYP3A5≤0.34 and Ki,3A5/Ki,3A4≥7, 
CYP3A5 non-expressers would have comparable or higher oral AUCR than expressers; 2) If 
fm, CYP3A5 ≥ 0.22 and Ki,3A5/Ki,3A4<7, CYP3A5 expressers would have higher oral AUCR than 
non-expressers and CYP3A5 is important for accurate predictions; and 3) If fm, CYP3A5 < 0.22 
but Ki,3A5/Ki,3A4<7, or fm, CYP3A5 > 0.34 but Ki,3A5/Ki,3A4> 7, the modeling framework should be 
used to predict the AUCR in different CYP3A5 phenotypes to support subject selection in 
study design and prioritization by bridging DDIs between the two groups.      
Such a roadmap has important clinical implications.  First, it helps set up criteria of initiating 
CYP3A5 genotyping and aids power analyses in designing CYP3A5 genetic studies by 
quantitatively predicting CYP3A5 genetic influence on PK.  Second, it applies to designing 
and conducting index or concomitant DDI studies for CYP3A substrates.  Itraconazole is a 
FDA-recommended index CYP3A inhibitor that preferentially inhibits CYP3A4 or 
Ki,3A5/Ki,3A4≥7 [18].  It is predicted that the magnitude of itraconazole interaction with a co-
substrate of CYP3A4 and CYP3A5 with fm, CYP3A5≤0.34, such as midazolam, would be lower in 
CYP3A5 expressers (Fig. 4 and Table S8), in agreement with a previous report [21].  
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expressers such as Africans and Asians [7] that the worst-case scenario of CYP3A inhibition 
may not be revealed.  Additional clinical CYP3A-mediated DDI studies in CYP3A5-genotyped 
populations for CYP3A drugs fm, CYP3A5 ≥ 0.34, i.e. tacrolimus and vincristine[35], may be 
warranted to advance understanding of role of CYP3A5 inhibition/content in adequate DDI 
predictions.  Another scenario is when conducting concomitant DDI studies using a co-
substrate of CYP3A4 and CYP3A5, such as simvastatin with equal CYP3A4 and CYP3A5 
contribution (fm, CYP3A5 ≥ 0.22) [36].  When Ki,3A5/Ki,3A4 is lower than five, the AUCR is 
predicted to be markedly higher in CYP3A5 expressers than that in non-expressers (Fig. 4 
and Table S8), and then DDIs from a study with primarily CYP3A5 non-expressers may not 
reflect those in expressers.  Although this scenario remains to be clinically validated, it 
deserves much attention considering the wide use of simvastatin in the polypharmacy era, 
less-well-understood CYP3A5 inhibition by known CYP3A4 inhibitors[37], as well as 
emerging compounds with potent CYP3A5 reversible inhibition (Ki,3A5/Ki,3A4 ≤1) in drug 
development.   
 
In conclusion, aided by a clinical CYP3A-mediated DDI study of oral and intravenous 
administration of midazolam with ketoconazole in different CYP3A5 genotypes, a PBPK 
framework incorporating proteomics-informed hepatic and small intestinal CYP3A 
abundance in combination with optimized small intestinal CYP3A4 content was qualified in 
SimCYP and used to predict CYP3A-mediated DDIs.  The modeling suggested the importance 
of evaluating the potential of an investigational drug to be a substrate and inhibitor of 
CYP3A5.  The PBPK modeling framework may be applied to PK and DDI studies of CYP3A 
substrate(s) in supporting study design and prioritization by bridging DDIs between CYP3A5 
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Methods  
Clinical Study 
  Subjects.  This study was approved by the Clarian and Indiana University Purdue University 
at Indianapolis institutional review board and the Research Involving Human Subjects 
Committee (FDA, DHSS).  Twenty-four volunteers participated in the study after giving 
written informed consent.  This 3-phase partially randomized cross-over study was 
conducted at the Indiana University General Clinical Research Center (GCRC).  There was a 
washout period of at least 7 days but no longer than 14 days between the two adjacent 
study phases.  All subjects were 18 years or older healthy subjects with inclusion criteria and 
clinical CYP3A5 genotyping methods were detailed in Supplementary Methods.   
  Study Phase 1 (Control Phase).  After an overnight fast, the volunteers received a 0.05 
mg/kg dose of midazolam (Versed®) infused intravenously over 30 minutes into an 
antecubital vein under the supervision of a physician.  Blood samples (5 ml) were collected 
from an indwelling venous catheter at the 0.5, 0.75, 1, 1.5, 2, 4, 6, 9, and 24 hours following 
the start of the infusion.  Subjects were allowed to eat 4 hours post dosing.  Immediately 
after the 24 hr blood collections, an oral dose of midazolam 4 mg (Roxane Laboratory, Inc., 
Columbus, OH) was administered with 240 ml of water, and blood samples were collected 
as described above.  
  Study Phase 2 and 3 (First and Second Ketoconazole Dosing).  The volunteers were 
randomized to receive ketoconazole 200 mg or 400 mg (Taro Pharmaceutical Industries Ltd, 
Hawthorne, NY) each morning with a can of caffeine-free cola (Coca-cola Company, Atlanta, 
Georgia) for 7-days.  On the sixth day of ketoconazole dosing, subjects returned to the GCRC 
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intravenously over 30 minutes and blood samples (7 mL) obtained as described in Phase 1.  
On the seventh day of ketoconazole, one hour after ketoconazole and 24 hours after 
midazolam administration on the previous day, a 1 mg of midazolam was orally 
administered and blood samples (7 mL) were collected as described in Phase 1.  The 
volunteers initiated the second ketoconazole regimen (200 mg or 400 mg) and underwent 
the same dosing and blood sampling as Phase 2.  Serum samples were stored at -20oC until 
analysis.  Serum concentrations of ketoconazole, midazolam and 1’-hydroxymidazolam were 
quantified by LC-MS as described previously [38, 39].  All data analysis were conducted and 
detailed in Supplementary Methods.  
 
In Vitro Studies 
  Human Liver and Small Intestinal Samples. A total of 136 human liver samples and 12 
human intestinal samples were utilized.  Among them, 121 human liver microsomes (HLMs) 
were isolated from human liver tissues as previously described [40] and the sample sources 
and demographics are provided in Table S10.  Additional 15 HLMs from donors previously 
confirmed for CYP3A5 genotypes were obtained from vendors.  The 12 human intestinal 
microsomes (HIMs) were acquired from Bioreclamation IVT (Baltimore, MD).  
 
  LC/MS Quantification of CYP3A Abundance. A stable isotope labeling (SIL)-based targeted 
quantitative proteomic approach was used to quantify CYP3A4 and CYP3A5 abundance in 
the 136 HLMs as previously described [15].  A similar approach was used to measure CYP3A4 
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peptides (L477SLGGLLQPEKPVVLK492 and D244TINFLSK251) were used to quantify CYP3A4 and 
CYP3A5, respectively (personal communication with Dr. Phil Smith).   
 
 In vitro CYP3A Midazolam Activity Assay.  CYP3A activity as measured by the formation of 
1’-hydroxymidazolam as a function of both the incubation time and protein concentration 
measured by BCA method, was quantified at a single substrate concentration of midazolam 
in 136 HLMs and 12 HIMs.  Details on the HLM and HIM samples, CYP3A5 genotyping, and in 
vitro CYP3A midazolam activity assay were described in Supplementary Methods.   
Modeling and Simulation. Modeling and simulations were performed in the SimCYP 
Population-Based PBPK Simulator® (version 17R1, Certara, Princeton, NJ) to 1) simulate 
CYP3A5 genetic impact on midazolam and tacrolimus in vivo clearance to verify use of 
LC/MS-measured CYP3A abundance, 2) qualify the modified ketoconazole model in SimCYP 
and then simulate midazolam-ketoconazole interactions, and 3) predict impact of CYP3A5 
expression on CYP3A-mediated disposition and DDIs in hypothetical studies.  The single 
absorption compartment first-order model was considered appropriate to reflect the 
absorption of substrates in immediate release formulations that have sufficient solubility 
and permeability to be absorbed in the small intestine where CYP3A enzymes are expressed 
[12]. Details on compound profile parameter settings, and the study design including study 
populations, drug administration, time course, and sampling are described in 
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Study Highlights 
What is the current knowledge on the topic? 
CYP3A4/5-mediated interactions are commonly encountered but challenging to predict due 
to the associated complexity. CYP3A4 and CYP3A5 share many common substrates, and the 
inhibition potency of many CYP3A inhibitors differ for CYP3A4 and CYP3A5.     
 
What question did this study address? 
Can we improve CYP3A4/5-mediated DDIs by verifying a PBPK model that brings together 
the relevant drug properties, physiological components including liver and gut CYP3A4/5, 
and CYP3A5 genetic polymorphisms?  
 
What does this study add to our knowledge? 
The presented PBPK modeling approach enables a better understanding of contribution of 
hepatic and small intestinal CYP3A4/5 abundance to the drug disposition and DDIs of CYP3A 
substrates.  Scenarios where CYP3A5 genotypes may significantly impact CYP3A-mediated 
DDIs are better understood and predicted.    
 
How might this change clinical pharmacology or translational science? 
A PBPK modeling framework incorporating proteomics-informed hepatic and small intestinal 
CYP3A abundance in combination with optimized small intestinal CYP3A4 content improves 
CYP3A-mediated DDI prediction.  For PK and DDI studies of CYP3A substrate(s), such a 
framework can inform study design and prioritization by bridging DDIs between CYP3A5 
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Figure Legends 
 
Figure 1. Serum (mean± SE) concentration-time profiles of midazolam via intravenous (a-c) 
and oral (d-f) administration in the absence (a and d, phase 1) and presence of 200 mg (b 
and e) or 400 mg (c and f) doses of ketoconazole (phase 2 and 3). CYP3A5 expressers are 
presented in solid lines and CYP3A5 non-expressers are presented in dotted lines.  
 
Figure 2. Relationships between CYP3A4 abundance, CYP3A5 abundance and CYP3A 
metabolic activity in human liver and small intestinal microsomal samples.  The correlation 
is shown between LC/MS-measured hepatic (a) and small intestinal (b) microsomal CYP3A4 
and CYP3A5 content in the CYP3A5 expressers, respectively, from the human liver samples 
(CYP3A5*1/*1: N=11, and CYP3A5*1/*3 or CYP3A5*1/*6: N=23) and small intestinal 
samples (CYP3A5*1/*1: N=2, and CYP3A5*1/*3: N=4).  Correlation of total CYP3A content 
with the CYP3A activity as measured by the formation rate of 1'-hydroxymidazolam is shown 
for the human hepatic (c) and small intestinal (d) microsomal samples.  Among the total 136 
liver tissues, 121 of them had microsomal samples for 1'-hydroxymidazolam formation 
assay, in which three CYP3A5*1/*1, one CYP3A5*1/*3, and 10 CYP3A5*3/*3 samples didn't 
have activity data.  Within the 12 small intestinal samples, one CYP3A5*1/*3 and two 
CYP3A5*3/*3 samples had activity data below the lower limit of quantification and were 
excluded from analyses, which led to nine samples that were used for the activity and 
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Figure 3. Observed and simulated intravenous (IV) and oral pharmacokinetic parameters 
(geometric mean) of midazolam following oral administration of 200 mg or 400 mg 
ketoconazole (KTZ) in CYP3A5 non-expressers (non-exp) and expressers (exp).  (a-c) The 
white and black bars represent, respectively, the observed and simulated midazolam IV 
blood clearance (a), oral blood clearance (b), and oral Cmax (maximum blood concentration) 
normalized by dose (c) following KTZ treatments.  (d-f) The white and black bars represent, 
respectively, the observed and simulated midazolam IV AUC ratio (d), oral AUC ratio (e), and 
Cmax/dose ratio (f) following KTZ treatments.  See Table S7 online more details.   
 
Figure 4. Simulated interaction trials (geometric mean) of hypothetical CYP3A substrates 
(with different Vmax ratio (CYP3A5/CYP3A4)) and hypothetical CYP3A inhibitors (with 
different Ki ratio (CYP3A5/CYP3A4)).  Hypothetical substrates differed from midazolam in 
ADME properties only in the relative contribution of hepatic CYP3A5 and CYP3A4 to 
metabolism, ranging from equal contribution to nine times of contribution from CYP3A5. 
This was reflected by changing the ratio of Vmax value of 1’-hydroxymidazolam formation 
by CYP3A5 to CYP3A4 from 2 to 18 while maintaining a constant value for the overall 
intrinsic clearance of CYP3A-mediated 1’-hydroxymidazolam formation. Hypothetical CYP3A 
inhibitors differed from ketoconazole only in the Ki ratio for CYP3A5 and CYP3A4, ranging 
from 1 to 7 while keeping the CYP3A4 Ki as 0.01 µM.  With the CLint ratio of CYP3A5 to 
CYP3A4 is 1, 2, 4, and 9, the hepatic clearance of CYP3A5 expressers is 1484, 1234, 1019, 
and 876 L/h, and fractional clearance of drugs by CYP3A5 (fm,CYP3A5) is 0.22, 0.34, 0.49 and 
0.65, respectively.  (a-b) The white and black bars represent the simulated IV (a) and oral (b) 
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expressers following KTZ treatments.  The numbers labelled on the top of black bars indicate 
the fold change in clearance values of CYP3A5 expressers relative to non-expressers.  (c-d) 
The white bars represent the AUC ratio in CYP3A5 non-expressers with and without an 
inhibitor of Ki,CYP3A4 of 0.01 µM.  Other symbols represent the AUC ratios in CYP3A5 
expressers with and without an inhibitor of Ki,CYP3A4 of 0.01 µM but different Ki ratio 
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Table 1.  Disposition of midazolam alone and following 200 mg or 400 mg doses of ketoconazole (KTZ) stratified by CYP3A5 genotypes 
  Control   200 mg KTZ   400 mg KTZ 




Expressers *3/*3 *3/*7   *1/*1 
*1/*3 and 
*1/*6 




Expressers *3/*3 *3/*7 
 
(n=6) (n=9) (n=15) (n=8) (n=1) 
            
Cmax /Dose 
(ng/mL) 
1.5 1.6 1.6 2.4 
3.4  
9.6 7.9 8.5 12.3 
18.1  
9.4 8.9 9.1 15.8 
21.2 
(24) (49) (40) (27) 
 
(42) (47) (44) (26) 
 




   
0.021 n/a 
   
0.0004 n/a 
                  
  Tmax (hr)*  
 
 
0.75 0.75 0.7 0.76 
1 
 
0.75 1 0.8 1.5 
1.5 
 


















                 
CLpo (L/hr) 
144 137 140 105 
55.7  
13.3 13.3 13.3 7.0 
4.6  
8.2 8.6 8.4 4.9 
2.7 
(21) (60) (47) (39) 
 
(41) (48) (47) (25) 
 






   
0.001 n/a 
   
0.001 n/a 
                  
CLsys (L/hr) 
32.4 33.0 32.8 24.1 
19.1  
11.6 12.5 12.1 7.1 
5.1  
7.6 9.0 8.4 5.2 
3.5 
(20) (28) (24) (17) 
 
(33) (43) (38) (28) 
 




   
0.001 n/a 
   
0.001 n/a 
                  
Fpo* 
0.22 0.23 0.23 0.26 0.36 
 
0.99 0.94 0.96 1.02 1.09 
 
0.93 1.05 1 1.08 1.33 
(16) (40) (31) (21) 
  
(16) (17) (16) (10) 
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t1/2 (hr)* 
2.76 2.75 2.75 3.05 5.25 
 
5.66 5.69 5.68 6.51 9.78 
 
8.83 8.72 8.77 8.92 19.28 
(57) (48) (49) (58) 
  
(29) (37) (33) (33) 
  
(35) (45) (40) (29) 
 
                  
1OH/MDZ 
AUCR 
0.53 0.40 0.45 0.34 0.44 
 
0.20 0.13 0.15 0.09 0.08 
 
0.12 0.11 0.11 0.05 0.06 
(39) (35) (38) (22) 
  
(32) (49) (47) (43) 
  
(46) (41) (42) (29) 
 
p-value#     0.038 n/a       0.017 n/a       0.00008 n/a 
 
Five CYP3A5 genotypes (mean±SD): CYP3A5*1/*1 (N=6; 4 males; BMI 25±3; age 34±14 ); CYP3A5*1/*3 (N=7; 7 males; BMI 27±3; age 31±10); CYP3A5*1/*6 (N=2); CYP3A5*3/*3 (N=8; 6 males; BMI 25±3; age 27±8); and 
CYP3A5*3/*7 (N=1).  Expressers: combined CYP3A5*1/*1, CYP3A5*1/*3, and CYP3A5*1/*6 genotype groups; Cmax, maximum blood concentration; Tmax, time of Cmax; CLpo, oral clearance; Fpo, oral bioavailability; CLsys, 
systemic clearance; t1/2, terminal half-life; 1OH/MDZ AUCR, 1’-hydoxymidazolam to midazolam plasma AUC ratio after IV midazolam.Averages are geometric means (coefficient of variation * 100) except for Tmax where the 
median and range is presented.  Comparison statistics: paired t-test of the log-transformed values, except for Tmax.  *No significant difference between expressers (CYP3A5*1/*1 and CYP3A5*1/*x) and non-expressers 
(CYP3A5*3/*3).  #Comparison of expressers and non-expressers; n/a not included in t-test.  Differences in pharmacokinetic parameters between genotypes and treatment phases were considered statically significant at the 
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Table 2. CYP3A abundance by CYP3A5 phenotypes in the human hepatic and small intestinal microsomal samples  
  
















































98 58.8* (93)   1.44 (127)   60.2 (90)   5 8.31* (74)   0.0724 (138)   8.39 (74)   
Unknown Unknown 4 52.8 (75)   1.4 (86)   54.2 (75)   NA 
Total   136 63.9 (96)   7.03 (210)   71 (97)   12 10.6 (72)   1.4 (101)   11.6 (68)   
 
#: Two CYP3A5*1/*6 were combined with CYP3A5*1/*3 into one group in the human hepatic microsomal samples.  One small intestinal microsomal samples with CYP3A5*1/*3 
genotype was excluded from CYP3A5 abundance data analyses as the CYP3A5 abundance was below the lower limit of quantification. 
&: Five hepatic and three small intestinal microsomal samples with CYP3A5*3/*3 genotypes were excluded from final data analyses as the CYP3A5 abundance was below the 
lower limit of quantification. 
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Table 3. Observed and simulated oral and systemic blood clearance values following a single dose of midazolam in 
healthy CYP3A5 expressers and non-expressers 
  
      
Clearance (L/hr) CL ratio of Exp to Non-
exp 
        IV Oral 
IV Oral 
        GM (90% CI)   GM (90% CI)   





 1.4 1.3 
  CYP3A5 expressers   32.8 (29.5-36.3)   140 (114.5-171.3)   
Scenario 
1 Simcyp default 
 
      





 1.5 3.3 
  CYP3A5 expressers   56.8 (55.1-58.6)   413.5 (382.1-447.5)   
Scenario 
2 Modified hepatic CYP3A abundance with measured CV + Simcyp intestinal CYP3A 
 
 CYP3A5 non-expressers 
 
22.6 (20.5- 24.8) 
 
62.8 (54.9-71.9) 
 1.4 2.0 
  CYP3A5 expressers   31.2 (29.1-33.5)   128.0 (113.9-143.8)   
Scenario 
3 
Modified hepatic CYP3A abundance with 50% of measured CV+ Simcyp intestinal CYP3A 
 





 1.3 2.0 
  CYP3A5 expressers   34.4 (32.7-36.3)   144.1 (132.1-157.2)   
Scenario 
4 
Modified hepatic CYP3A abundance with 33% of measured CV+ Simcyp intestinal CYP3A  





 1.3 2.0 
  CYP3A5 expressers   35.3 (33.8-36.9)   148.1 (137.2-160.0)   
Scenario 
5 
Modified hepatic CYP3A abundance with 33% of measured CV+ modified intestinal CYP3A 





 1.3 1.8 
  CYP3A5 expressers   35.6 (33.8-37.1)   185.3 (168.2-200.9)   
CV: coefficient of variation; GM: geometric mean; SD: standard deviation; CL: clearance 
Simulation scenarios: 1) SimCYP values for hepatic and small intestinal CYP3A abundance and variability; 2-4) 
LC/MS-measured hepatic CYP3A abundance with adjusted variability plus SimCYP small intestinal CYP3A 
abundance and variability; and 5) LC/MS-measured hepatic CYP3A abundance with optimized variability plus 
optimized small intestinal CYP3A abundance 
Correlation for the modified hepatic CYP3A4 and CYP3A5 abundance in CYP3A5 expressers is described as (in 
pmol/mg) CYP3A5 = 0.18*CYP3A4 + 9.55. Simulations were conducted in total 100 healthy subjects including 10 
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